Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Lapatinib in Combination With Everolimus in Triple Negative Metastatic or Locally Advanced Breast Cancer

NCT01272141 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT01272141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01272141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Lapatinib in Combination With Everolimus in Triple Negative Metastatic or Locally Advanced Breast Cancer
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2010
Completion date
January 31, 2014
Enrollment
5 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasms, cancer of the breast